321 results
424B5
INO
Inovio Pharmaceuticals Inc
17 Apr 24
Prospectus supplement for primary offering
4:02pm
of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do … product candidates. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA
8-K
EX-99.1
j6kcc
9 Nov 23
INOVIO Reports Third Quarter 2023 Financial Results
4:15pm
8-K
EX-99.1
yswid38sx3ilw2i 0bl
10 Oct 23
INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program
4:00pm
8-K
EX-99.1
hks1g 5pc5ht
9 Aug 23
INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update
4:23pm
8-K
EX-99.1
i2qd zpx8q5n
23 Jun 23
Regulation FD Disclosure
4:25pm
8-K
EX-99.1
rltla86c0gq1 3odlcpd
10 May 23
INOVIO Reports First Quarter 2023
4:20pm
8-K
EX-99.1
tb8rbn5bk
8 Nov 22
INOVIO Reports Financial Results and Highlights for the Third Quarter 2022
4:13pm
CORRESP
jd10gaw xk3
29 Sep 22
Correspondence with SEC
12:00am
UPLOAD
rd51w jhs6rsge44is2k
15 Sep 22
Letter from SEC
12:00am
8-K
qcvif 75nl
19 Jul 22
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients
8:53am
8-K
EX-99.1
h8yhe5ghltgai
19 Jul 22
INOVIO Announces Corporate Reorganization to Reduce Operational Expenses and Focus on Opportunities to Bring the Promise of DNA Medicines to Patients
8:53am